Stay updated on EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial page.

Latest updates to the EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial page
- ChecktodayChange DetectedA new revision entry v3.3.4 was added to the record history and the previous v3.3.3 entry was removed.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a new revision entry 'Revision: v3.3.3' to the Record History. Removed the 'HHS Vulnerability Disclosure' footer link and the older revision 'Revision: v3.3.2' from the page.SummaryDifference0.2%

- Check50 days agoChange DetectedRecord History now lists Revision v3.3.2 and removes Revision v3.2.0.SummaryDifference0.1%

- Check57 days agoChange DetectedThe operating-status notice about government funding was removed from the page.SummaryDifference0.7%

- Check72 days agoChange DetectedThe screenshots show the Record History page for NCT02183870 with version entries from 2014 to 2022. The content and structure remain consistent, with only minor UI updates.SummaryDifference0.1%

- Check100 days agoChange DetectedAdded a prominent operating-status notice and a new version tag (v3.2.0); removed the old version tag (v3.1.0).SummaryDifference12%

Stay in the know with updates to EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the EUCROSS: Crizotinib in ROS1+ Lung Cancer Clinical Trial page.